- Home
- GBLI vs AUTL Comparison
GBLI vs AUTL Comparison
Compare GBLI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | AUTL |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.4M | 431.2M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GBLI | AUTL |
|---|---|---|
| Price | $28.58 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.3K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $450,098,000.00 | $10,120,000.00 |
| Revenue This Year | $14.23 | $84.74 |
| Revenue Next Year | $9.68 | $65.76 |
| P/E Ratio | $16.33 | ★ N/A |
| Revenue Growth | 2.02 | ★ 496.00 |
| 52 Week Low | $25.88 | $1.15 |
| 52 Week High | $34.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | GBLI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 59.85 |
| Support Level | $28.50 | $1.22 |
| Resistance Level | $28.81 | $1.69 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 100.00 | 74.03 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.